NCT02083406已完成1 期
Open Label Study to Investigate the Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects
Medicines for Malaria Venture1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2014年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- OZ439 AUC(0-168h)
研究概览
简要总结
A single dose study to investigate how different formulations of OZ439 co-administered with PQP tablest are processed by the body when taken without food
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males, or healthy females of non-childbearing potential ie surgically sterilised or post-menopausal (amenorrhoea for at least 1 year and confirmed by a follicle stimulating hormone result of ≥25 IU/mL
- •Age 18 to 55 years of age
- •Body mass index of 18.0 to 30.0 kg/m2 inclusive. Total body weight >50 kg at screening
- •Willing and able to communicate and participate in the whole study
- •Must provide written informed consent
- •Must agree to use an adequate method of contraception
- •Must have liver function tests and haemoglobin within the laboratory reference range at screening and Day -1
- •Must have heart trace measurements within the defined healthy limits at screening, Day -1 and pre-dose
排除标准
- •Male subjects who have currently pregnant partners
- •Evidence or history of clinically significant oncological, pulmonary, chronic respiratory, hepatic, cardiovascular, haematological, metabolic, neurological, immunological, nephrological, endocrine or psychiatric disease, or current infection
- •Clinically relevant abnormalities in the heart trace including any degree of heart block, including asymptomatic bundle branch block
- •Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval
- •History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia
- •Electrolyte disturbances, particularly hypokalemia, hypocalcaemia or hypomagnesaemia.
- •Any condition that could possibly affect drug absorption, such as gastrectomy or diarrhoea
- •History of post-antibiotic colitis
- •History of any drug or alcohol abuse in the past 2 years prior to screening
- •Subjects who have a breath carbon monoxide reading of greater than 10 ppm at screening will be excluded. Subjects who are tobacco users (including smokers and users of snuff, chewing tobacco and other nicotine or nicotine-containing products) must have stopped use within 90 days before screening.
- •Receipt of an investigational drug or participation in another clinical research study within 90 days prior to drug administration.
- •Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
- •Subjects who have previously been enrolled in this study
- •Use of ANY prescription or non-prescription medications, vitamins, herbal supplements or dietary supplements, including protein supplements, within 14 days prior to the first dose of study drug and throughout the study, unless prior approval is granted by both the investigator and the sponsor. An exception will be made for intermittent use of paracetamol and hormone replacement therapy. Paracetamol at doses of, at most, 2 g per day or no more than 3 consecutive days or 6 non consecutive days, are allowed until 24 hours before dosing with study drug. Longer exclusion periods apply for:
- •amiodarone and hydroxychloroquine (210 days)
- •monoclonal antibodies/ immunoglobulins/ other therapeutic proteins and experimental drugs for which the half-life is not known to the investigator (120 days)
- •experimental drugs for which half-life is known to the investigator (5 half lives plus 14 days)
- •chloroquine, piperaquine phosphate and flunarizine (100 days)
- •fluoxetine (75 days)
- •benzodiazepines (for midazolam, lorazepam and triazolam, the exclusion period is 14 days), chlorpromazine, mephenytoin, nortryptyline, phenobarbital, primidone, phenprocoumone and cytochrome P450 3A4 inducers not already mentioned, including but not restricted to, rifampin, carbamazepine, oxcarbazepine, phenytoin and St John's Wort (35 days)
- •Positive hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus results
- •Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator
- •Positive urine drug screen result at screening or admission to the clinical unit
- •History of intolerance or hypersensitivity to piperaquine or any 4-aminoquinolone, or ascertained or presumptive hypersensitivity to the active principle and/or formulation ingredients; history of anaphylaxis to drugs or allergic reactions in general, that the investigator considers may affect the outcome of the study
- •Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- •Presence or history of allergy requiring treatment; hayfever is allowed unless it is active
- •Donation or loss of >400 mL of blood within 90 days prior to drug administration
- •Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
- •Subjects who do not have suitable veins for multiple blood samples as assessed by the investigator at screening
- •Failure to satisfy the investigator of fitness to participate for any other reason
研究组 & 干预措施
Treatment A: OZ439 Prototype 1
Experimental
800mg OZ439 prototype formulation 1 and 960mg PQP single doses
干预措施: 800mg OZ439 prototype formulation 1 (Drug)
Treatment A: OZ439 Prototype 1
Experimental
800mg OZ439 prototype formulation 1 and 960mg PQP single doses
干预措施: 960mg PQP (Drug)
Treatment B: OZ439 Prototype 2
Experimental
800mg OZ439 prototype formulation 2 and 960mg PQP single doses
干预措施: 800mg OZ439 prototype formulation 2 (Drug)
Treatment B: OZ439 Prototype 2
Experimental
800mg OZ439 prototype formulation 2 and 960mg PQP single doses
干预措施: 960mg PQP (Drug)
Treatment C: OZ439 Prototype 3
Experimental
800mg OZ439 prototype formulation 3 and 960mg PQP single doses
干预措施: 800mg OZ439 prototype formulation 3 (Drug)
Treatment C: OZ439 Prototype 3
Experimental
800mg OZ439 prototype formulation 3 and 960mg PQP single doses
干预措施: 960mg PQP (Drug)
结局指标
主要结局
OZ439 AUC(0-168h)
时间窗: Up to 168 hours post-dose
OZ439 Area under the plasma concentration (AUC) versus time curve
OZ439 Cmax
时间窗: Up to 168 hours post-dose
OZ439 Maximum observed concentration
次要结局
- Piperaquine (PQ) AUC(0-168h)(Up to 168h post-dose)
- PQ Cmax(Up to 168h post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy VolunteersMalariaNCT01958619Medicines for Malaria Venture55
已完成
1 期
Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male VolunteersEssential HypertensionNCT00937534Boryung Pharmaceutical Co., Ltd22
已完成
1 期
Pharmacokinetics and Safety of ORF Tablets in Pediatric PatientsOpioid AnalgesiaNCT01160614Purdue Pharma LP30
已完成
1 期
A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961Healthy SubjectsNCT03492697Pfizer12
已完成
1 期
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer SubjectsHealthyNCT01416207Biogen24